An adaptive biomarker basket design in phase II oncology trials. (26th September 2022)

• Record Type: Journal Article
• Authors: Liu, Shufang; Takeda, Kentaro; Rong, Alan
• Is Part Of: Pharmaceutical statistics. Volume 22:Number 1(2023)
• Page Start: 128
• Page End: 142
• Publication Date: 2022-09-26
• Subjects: adaptive biomarker basket design -- biomarker cutoff -- biomarker enrichment trial -- hierarchical Bayesian model with biomarker as a covariate -- oncology -- phase II basket trial; Pharmacy -- Statistical methods -- Periodicals; Pharmacy -- Statistics -- Periodicals; 615.10727
• DOI: 10.1002/pst.2264
• Languages: English
• ISSNs: 1539-1604

Abstract

Abstract: The phase II basket trial in oncology is a novel design that enables the simultaneous assessment of treatment effects of one anti‐cancer targeted agent in multiple cancer types. Biomarkers could potentially associate with the clinical outcomes and re‐define clinically meaningful treatment effects. It is therefore natural to develop a biomarker‐based basket design to allow the prospective enrichment of the trials with the adaptive selection of the biomarker‐positive (BM+) subjects who are most sensitive to the experimental treatment. We propose a two‐stage phase II adaptive biomarker basket (ABB) design based on a potential predictive biomarker measured on a continuous scale. At Stage 1, the design incorporates a biomarker cutoff estimation procedure via a hierarchical Bayesian model with biomarker as a covariate (HBMbc). At Stage 2, the design enrolls only BM+ subjects, defined as those with the biomarker values exceeding the biomarker cutoff within each cancer type, and subsequently assesses the early efficacy and/or futility stopping through the pre‐defined interim analyses. At the end of the trial, the response rate of all BM+ subjects for each cancer type can guide drug development, while the data from all subjects can be used to further model the relationship between the biomarker value and the clinical outcome for potential future research. The extensive simulation studies show that the ABB design could produce a good estimate of the biomarker cutoff to select BM+ subjects with high accuracy and could outperform the existing phase II basket biomarker cutoff design under various scenarios.